-92%

est. 2Y upside i

HealthcareSeed

The Best Data Infrastructure for Biotechs

Rank

#3718

Sector

Life Sciences / Biotech Data Infrastructure

Est. Liquidity

~5Y

Data Quality

Data: Medium

Scispot offers a compelling vision for AI-driven, no-code lab automation in a growing market, but the equity opportunity is highly speculative due to extremely limited funding and intense competition from a dominant incumbent.

Last updated: February 16, 2026

Bull (8%)+400%

Scispot successfully secures significant follow-on funding, rapidly expands its customer base by leveraging its AI and no-code differentiators, and carves out a substantial niche despite incumbent competition.

Base (42%)+50%

Scispot achieves moderate growth, secures a modest Series A round, but continues to face strong competitive pressure, leading to a limited but positive return for early equity holders.

Bear (50%)-90%

Scispot struggles to raise further capital, fails to gain significant market traction against dominant competitors, or is acquired for a minimal amount, resulting in substantial equity loss.

Est. time to liquidity~5.0 years
View all 11 open roles at Scispot →

Last updated: March 10, 2026

Community

Valuation Sentiment

Our model estimates -92% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.